Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALNY
CUSIP02043Q10
Phone617-551-8200
Debt
Debt-to-Equity Ratio0.02
Current Ratio14.61
Quick Ratio14.61
Price-To-Earnings
Trailing P/E Ratio-18.95
Forward P/E Ratio-15.33
P/E GrowthN/A
Sales & Book Value
Annual Sales$89.91 million
Price / Sales114.81
Cash FlowN/A
Price / CashN/A
Book Value$17.96 per share
Price / Book5.72
Profitability
EPS (Most Recent Fiscal Year)($5.42)
Net Income$-490,870,000.00
Net Margins-565.20%
Return on Equity-36.81%
Return on Assets-31.28%
Miscellaneous
Employees749
Outstanding Shares100,520,000
Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions
What is Alnylam Pharmaceuticals' stock symbol?
Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."
How were Alnylam Pharmaceuticals' earnings last quarter?
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its quarterly earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, beating analysts' consensus estimates of ($1.47) by $0.06. The biopharmaceutical company had revenue of $21.90 million for the quarter, compared to analysts' expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business's revenue was up 15.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.25) earnings per share. View Alnylam Pharmaceuticals' Earnings History.
When is Alnylam Pharmaceuticals' next earnings date?
What price target have analysts set for ALNY?
20 brokers have issued 12 month price targets for Alnylam Pharmaceuticals' stock. Their forecasts range from $56.00 to $207.00. On average, they expect Alnylam Pharmaceuticals' share price to reach $142.25 in the next twelve months. View Analyst Ratings for Alnylam Pharmaceuticals.
What are Wall Street analysts saying about Alnylam Pharmaceuticals stock?
Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Alnylam posted wider than expected loss and missed revenue estimates in the first quarter of 2018. The company reported positive data from the ATLAS study which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020. Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company." (5/10/2018)
- 2. Chardan Capital analysts commented, "We now raise our PT to $175, after: (1) increasing the patisiran probability of success to 97%, and (2) lowering the Alnylam WACC to 8% to reflect further RNAi therapeutics platform de-risking. We now update our Alnylam patient-based and other models to reflect recent positives, while consolidating views from recent Chardan macro research (e.g. on novel lipid-lowering therapies). (See Figures 3-7.) Notably, a near- best-case safety and efficacy profile emerged from the pivotal APOLLO trial (as discussed in our 20 September 2017 research); and, Alnylam proceeded to file patisiran in an expeditious fashion. We thus newly model a 97% probability of success (POS) for patisiran and $1.77 billion in 2030E risk-adjusted franchise sales (patisiran and follow ons). We now increase the POS of givosiran, to 80% ($540 million in 2030E sales) from 40% in our previous model, given the product’s progress ahead of our expectations." (1/19/2018)
- 3. FBR & Co analysts commented, "We are initiating coverage of Alnylam Pharmaceuticals, Inc. (ALNY), making it our Alpha Generator pick, with a Buy rating and a 12-month price target of $150 per share, due to our utmost conviction that Alnylam represents a foundational biopharma investment, led by the firm’s hereditary transthyretin amyloidosis (hATTR) franchise." (10/30/2017)
- 4. Needham & Company LLC analysts commented, "Alnylam announced today that dosing of fitusiran, in development for Hemophilia, has been suspended in all clinical trials. A patient death tied to a thrombotic event was reported in ongoing Phase 2 OLE trial and FDA has issued a clinical hold. Alnylam had just initiated a Phase 3 program in Jul 2017. The incident raises questions around safety margin for the drug. Fitusiran is intended to increase thrombin levels closer to normal range. Concerns, however, have been raised around risk of thrombosis if thrombin levels are too high, particularly when used w/ on-demand factor or bypassing agents. Based on available clinical data, we believe fitusiran allows for better control of Hemophilia, but patients and physicians may have a narrower safety window when managing bleeds. Our bias is Alnylam and FDA will reach agreement on a protocol to more closely monitor patients and that clinical development will resume over next 3-6 months. We continue to believe in long-term value of RNAi, but acknowledge greater risk than we anticipated around fitusiran. We have reduced our fitusiran estimates to reflect delayed launch and slower market penetration." (9/7/2017)
Who are some of Alnylam Pharmaceuticals' key competitors?
Some companies that are related to Alnylam Pharmaceuticals include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Jazz Pharmaceuticals (JAZZ) and Perrigo (PRGO).
Who are Alnylam Pharmaceuticals' key executives?
Alnylam Pharmaceuticals' management team includes the folowing people:
- Dr. John M. Maraganore, CEO & Exec. Director (Age 55)
- Mr. Barry E. Greene, Pres (Age 55)
- Mr. John K. Clarke, Founder & Director (Age 64)
- Dr. Phillip A. Sharp, Co-Founder, Director & Member of the Scientific Advisory Board (Age 73)
- Yvonne Greenstreet, Chief Operating Officer and Exec. VP (Age 55)
Has Alnylam Pharmaceuticals been receiving favorable news coverage?
News headlines about ALNY stock have trended somewhat positive on Thursday, Accern reports. The research firm scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Alnylam Pharmaceuticals earned a coverage optimism score of 0.24 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.95 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Alnylam Pharmaceuticals' major shareholders?
Alnylam Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.14%), Baillie Gifford & Co. (3.81%), BB Biotech AG (1.01%), Point72 Asset Management L.P. (0.90%), Artal Group S.A. (0.60%) and Northern Trust Corp (0.47%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, David E I Pyott, Dennis A Ausiello, John Maraganore, Laurie Keating, Michael Mason, Paul Schimmel, Philip A Sharp, Sanofi and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.
Which major investors are selling Alnylam Pharmaceuticals stock?
ALNY stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Slate Path Capital LP, Artal Group S.A., Swiss National Bank, BB Biotech AG, Opus Point Partners Management LLC, Eventide Asset Management LLC and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, Dennis A Ausiello, John Maraganore, Laurie Keating, Michael Mason, Paul Schimmel, Philip A Sharp and Yvonne Greenstreet. View Insider Buying and Selling for Alnylam Pharmaceuticals.
Which major investors are buying Alnylam Pharmaceuticals stock?
ALNY stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Farallon Capital Management LLC, Rockefeller Capital Management L.P., Legal & General Group Plc, Baillie Gifford & Co., Green Valley Investors LLC, Eversept Partners LLC and Franklin Resources Inc.. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include David E I Pyott, Laurie Keating and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.
How do I buy shares of Alnylam Pharmaceuticals?
Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alnylam Pharmaceuticals' stock price today?
One share of ALNY stock can currently be purchased for approximately $102.69.
How big of a company is Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals has a market capitalization of $10.52 billion and generates $89.91 million in revenue each year. The biopharmaceutical company earns $-490,870,000.00 in net income (profit) each year or ($5.42) on an earnings per share basis. Alnylam Pharmaceuticals employs 749 workers across the globe.
How can I contact Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals' mailing address is 300 THIRD STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]
MarketBeat Community Rating for Alnylam Pharmaceuticals (ALNY)
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
